CoChat

Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A

Open access

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Alzheimer's disease (AD)-linked β-amyloid (Aβ) accumulates in multivesicular bodies (MVBs) with the onset of AD pathogenesis. Alterations in endosomes are among the earliest changes associated with AD but the mechanism(s) that cause endosome enlargement and the effects of MVB dysfunction on Aβ accumulation and tau pathology are incompletely understood. METHODS: MVB size and Aβ fibrils in primary neurons were visualized by electron microscopy and confocal fluorescent microscopy. MVB-dysfunction, modelled by expression of dominant negative VPS4A (dnVPS4A), was analysed by biochemical methods and exosome isolation. RESULTS: Here we show that AD transgenic neurons have enlarged MVBs compared to wild type neurons. Uptake of exogenous Aβ also leads to enlarged MVBs in wild type neurons and generates fibril-like structures in endocytic vesicles. With time fibrillar oligomers/fibrils can extend out of the endocytic vesicles and are eventually detectable extracellularly. Further, endosomal sorting complexes required for transport (ESCRT) components were found associated with amyloid plaques in AD transgenic mice. The phenotypes previously reported in AD transgenic neurons, with net increased intracellular levels and reduced secretion of Aβ, were mimicked by blocking recycling of ESCRT-III by dnVPS4A. DnVPS4A further resembled AD pathology by increasing tau phosphorylation at serine 396 and increasing markers of autophagy. CONCLUSIONS: We demonstrate that Aβ leads to MVB enlargement and that amyloid fibres can form within the endocytic pathway of neurons. These results are consistent with the scenario of the endosome-lysosome system representing the site of initiation of Aβ aggregation. In turn, a dominant negative form of the CHMP2B-interacting protein VPS4A, which alters MVBs, leads to accumulation and aggregation of Aβ as well as tau phosphorylation, mimicking the cellular changes in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13024-017-0203-y

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Aβ increases MVB diameter in primary neurons. a Electron microscopy reveals that APP/PS1 AD transgenic compared to wt mouse primary neurons have significantly larger MVBs at 12 DIV. Scale bar 500 nm. b Quantification of A shows an increase of 52% in MVB diameter in Tg compared to wt neurons, n > 94 MVBs per group; *** p < 0.001. c Exogenously added monomeric Aβ1-40 or Aβ1-42 to wt primary neurons at 12 DIV leads to increased MVB diameter at 48 h on EM images. MVBs are marked with an asterisk. Scale bar 500 nm. d Quantification of C, n > 45 MVBs per group; *** p < 0.001. e Shorter time-points of exogenously added monomeric Aβ1-42 already leads to increased size of LAMP1-positive vesicles 3 h after treatment in wt mouse neurons at 12 DIV; 3D-rendering with Imaris from confocal z-stack. High magnification image of LAMP1 labelling from a single focal plane to the right. Scale bar 10 μm. f Quantification of E shows significant increase in diameter of LAMP1-positive vesicles after addition of Aβ. The diameters of the five largest LAMP1-positive vesicles per pyramidal neuron were measured in the z-stacks; n > 10 neurons per treatment; **** p < 0.0001
Fig. 1 Aβ increases MVB diameter in primary neurons. a Electron microscopy reveals that APP/PS1 AD transgenic compared to wt mouse primary neurons have significantly larger MVBs at 12 DIV. Scale bar 500 nm. b Quantification of A shows an increase of 52% in MVB diameter in Tg compared to wt neurons, n > 94 MVBs per group; *** p < 0.001. c Exogenously added monomeric Aβ1-40 or Aβ1-42 to wt primary neurons at 12 DIV leads to increased MVB diameter at 48 h on EM images. MVBs are marked with an asterisk. Scale bar 500 nm. d Quantification of C, n > 45 MVBs per group; *** p < 0.001. e Shorter time-points of exogenously added monomeric Aβ1-42 already leads to increased size of LAMP1-positive vesicles 3 h after treatment in wt mouse neurons at 12 DIV; 3D-rendering with Imaris from confocal z-stack. High magnification image of LAMP1 labelling from a single focal plane to the right. Scale bar 10 μm. f Quantification of E shows significant increase in diameter of LAMP1-positive vesicles after addition of Aβ. The diameters of the five largest LAMP1-positive vesicles per pyramidal neuron were measured in the z-stacks; n > 10 neurons per treatment; **** p < 0.0001CC BY · PubMed Central
Fig. 2 Fibril-like structures in endocytic organelles of wild-type neurons treated with Aβ1-42. a Wt primary neurons treated at 12 DIV with Aβ for 48 h induced fibril-like structures in endocytic organelles with Aβ1-42. BSA-gold was added to cells 2 h before fixation to delineate endocytic organelles (marked with asterisk). Scale bar 500 nm. High magnification image to the right, scale bar 100 nm. b Aβ1-42 peptides incubated in vitro at 37 °C for 1 h to induce fibril formation, imaged with EM. Scale bar 100 nm. c BSA-gold (white arrows) was found in the cytosol in Aβ1-42 treated neurons, indicating loss of endolysosomal impermeability due to Aβ1-42. Scale bar 500 nm. d OC antibody labelling for fibrillar oligomers and/or fibrils is seen in a vesicular pattern in processes after 45 min treatment with 0.5 μM of Aβ1-42 and colocalizes with human Aβ antibody 6E10 confirming that fibrils consist of the added human Aβ1-42. Scale bar 10 μm. e Feeding 0.5 μM of Aβ1-42 to wt primary neurons at 12 DIV at 24 h vs 48 h. At 24 h most of the OC labelling was also antibody 6E10 positive. At 48 h the outer aspects of OC positive structures were 6E10 negative. Scale bar 20 μm. f Weak surface labelling of non-permeabilized neurons shows that OC and 6E10 antibody positive structures were intracellular after 24 h of treatment with Aβ1-42 (upper panel). At 48 h extracellular OC antibody labelling was now more visible consistent with penetration of the plasma membrane by the elongated OC positive fibrils (middle panel). Strong OC and 6E10 antibody labelling of permeabilized cells after fixation but before immunolabelling, shows that the vast majority of added human Aβ1-42 (antibody 6E10) and OC antibody positive fibrils and/or fibrillar oligomers are inside neurons (lower panel). Scale bar 20 μm. g After 48 h of treatment with 0.5 μM Aβ1-42, OC antibody labelling was seen extending out from LAMP1-positive structures in the processes. The image shows OC with the superimposed colocalizing channel for LAMP1 and OC. For the complete image with separate channels see Additional file 3: S2A. Scale bar 20 μm
Fig. 2 Fibril-like structures in endocytic organelles of wild-type neurons treated with Aβ1-42. a Wt primary neurons treated at 12 DIV with Aβ for 48 h induced fibril-like structures in endocytic organelles with Aβ1-42. BSA-gold was added to cells 2 h before fixation to delineate endocytic organelles (marked with asterisk). Scale bar 500 nm. High magnification image to the right, scale bar 100 nm. b Aβ1-42 peptides incubated in vitro at 37 °C for 1 h to induce fibril formation, imaged with EM. Scale bar 100 nm. c BSA-gold (white arrows) was found in the cytosol in Aβ1-42 treated neurons, indicating loss of endolysosomal impermeability due to Aβ1-42. Scale bar 500 nm. d OC antibody labelling for fibrillar oligomers and/or fibrils is seen in a vesicular pattern in processes after 45 min treatment with 0.5 μM of Aβ1-42 and colocalizes with human Aβ antibody 6E10 confirming that fibrils consist of the added human Aβ1-42. Scale bar 10 μm. e Feeding 0.5 μM of Aβ1-42 to wt primary neurons at 12 DIV at 24 h vs 48 h. At 24 h most of the OC labelling was also antibody 6E10 positive. At 48 h the outer aspects of OC positive structures were 6E10 negative. Scale bar 20 μm. f Weak surface labelling of non-permeabilized neurons shows that OC and 6E10 antibody positive structures were intracellular after 24 h of treatment with Aβ1-42 (upper panel). At 48 h extracellular OC antibody labelling was now more visible consistent with penetration of the plasma membrane by the elongated OC positive fibrils (middle panel). Strong OC and 6E10 antibody labelling of permeabilized cells after fixation but before immunolabelling, shows that the vast majority of added human Aβ1-42 (antibody 6E10) and OC antibody positive fibrils and/or fibrillar oligomers are inside neurons (lower panel). Scale bar 20 μm. g After 48 h of treatment with 0.5 μM Aβ1-42, OC antibody labelling was seen extending out from LAMP1-positive structures in the processes. The image shows OC with the superimposed colocalizing channel for LAMP1 and OC. For the complete image with separate channels see Additional file 3: S2A. Scale bar 20 μmCC BY · PubMed Central
Fig. 3 Aβ42 increases high molecular weight complexes of CHMP2B and ESCRT proteins accumulate in amyloid plaques. a Immunolabelling of APP/PS1 transgenic primary neurons shows Aβ42 colocalizing with CHMP2B-positive vesicles. Scale bar 10 μm, n = 3. b A trend for increased high molecular weight complexes of CHMP2B, a 24 kDa ESCRT-III component, in APP/PS1 transgenic compared to wt neurons is seen on native gel. Treatment with 0.5 μM of Aβ1-42 for 3 h further increases these high molecular weight complexes. However only APP/PS1 transgenic neurons treated with Aβ1-42 show a statistically significant increase in high molecular weight complexes compared to wt. Equal amounts of total protein were loaded into the wells, n = 6; *p < 0.05. c VPS4 colocalizes with Aβ42 in amyloid plaques of 19-month-old APP/PS1 mice. Scale bar 40 μm, n = 4. d Tsg101 colocalizes with both Aβ42 and the neuronal-specific endo-lysosomal marker clavesin 1 and 2 in amyloid plaques of 19-month-old APP/PS1 mice. Scale bar 40 μm, n = 3. e In early plaques present in the 3-month-old Tg19959 mice Tsg101 also colocalized with Aβ42. Scale bar 40 μm, n = 3
Fig. 3 Aβ42 increases high molecular weight complexes of CHMP2B and ESCRT proteins accumulate in amyloid plaques. a Immunolabelling of APP/PS1 transgenic primary neurons shows Aβ42 colocalizing with CHMP2B-positive vesicles. Scale bar 10 μm, n = 3. b A trend for increased high molecular weight complexes of CHMP2B, a 24 kDa ESCRT-III component, in APP/PS1 transgenic compared to wt neurons is seen on native gel. Treatment with 0.5 μM of Aβ1-42 for 3 h further increases these high molecular weight complexes. However only APP/PS1 transgenic neurons treated with Aβ1-42 show a statistically significant increase in high molecular weight complexes compared to wt. Equal amounts of total protein were loaded into the wells, n = 6; *p < 0.05. c VPS4 colocalizes with Aβ42 in amyloid plaques of 19-month-old APP/PS1 mice. Scale bar 40 μm, n = 4. d Tsg101 colocalizes with both Aβ42 and the neuronal-specific endo-lysosomal marker clavesin 1 and 2 in amyloid plaques of 19-month-old APP/PS1 mice. Scale bar 40 μm, n = 3. e In early plaques present in the 3-month-old Tg19959 mice Tsg101 also colocalized with Aβ42. Scale bar 40 μm, n = 3CC BY · PubMed Central
Fig. 4 DnVPS4A causes increased accumulation and reduced secretion of Aβ42. Expression of control plasmid (ctr), wtVPS4A (wtVPS4) or the ATP hydrolysis deficient mutant dnVPS4A (dnVPS4) in Swe N2a cells (A-H) or wt primary mouse neurons (I) for 24 h. a Representative Western blot of APP, SDS-stable oligomeric Aβ species, β-CTFs and monomeric Aβ in cell lysate probed with antibody 6E10, and β-actin for protein normalization. b Western blot analysis of full length APP, β-CTFs and α-CTFs in cell lysate probed with the C-terminal specific APP antibody 369. c Western blot analysis of secreted αAPP (sAPPα) and Aβ in cell medium with antibody 6E10. d Densitometric quantification of A and C demonstrates that expression of dnVPS4, but not wtVPS4, increases intracellular Aβ compared to ctr. On the other hand, both wtVPS4A and dnVPS4A reduces secreted Aβ compared to ctr, although to a greater extent with dnVPS4A. DnVPS4 increases both cellular and secreted APP. Values are normalized against actin and expressed as percentage of control, n > 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. e Cellular full length APP is increased in cells transfected with dnVPS4A-FLAG (lower panel) compared to control plasmid Ctr-FLAG (upper panel). Scale bar 25 μm. f Antibody OC labelling of fibrillar oligomers and fibrils is increased in cells transfected with dnVPS4A (arrows) compared to control plasmid. Scale bar 25 μm. g Antibody OC labelling in dnVPS4-transfected cells is associated with enlarged vesicles positive for flotillin-1. Scale bar 15 μm. h Aβ42 accumulation in vesicles positive for ESCRT protein Tsg101 in dnVPS4A-transfected cells. Scale bar 25 μm. i Wt primary neurons at 12 DIV transfected with synapsin-dnVPS4A-FLAG or control synapsin-GFP plasmid for 24 h, immunolabelled for Aβ42 and the post-synaptic protein drebrin shows that Aβ42 labelling is increased with expression of dnVPS4A but not with control plasmid. Scale bar 50 μm
Fig. 4 DnVPS4A causes increased accumulation and reduced secretion of Aβ42. Expression of control plasmid (ctr), wtVPS4A (wtVPS4) or the ATP hydrolysis deficient mutant dnVPS4A (dnVPS4) in Swe N2a cells (A-H) or wt primary mouse neurons (I) for 24 h. a Representative Western blot of APP, SDS-stable oligomeric Aβ species, β-CTFs and monomeric Aβ in cell lysate probed with antibody 6E10, and β-actin for protein normalization. b Western blot analysis of full length APP, β-CTFs and α-CTFs in cell lysate probed with the C-terminal specific APP antibody 369. c Western blot analysis of secreted αAPP (sAPPα) and Aβ in cell medium with antibody 6E10. d Densitometric quantification of A and C demonstrates that expression of dnVPS4, but not wtVPS4, increases intracellular Aβ compared to ctr. On the other hand, both wtVPS4A and dnVPS4A reduces secreted Aβ compared to ctr, although to a greater extent with dnVPS4A. DnVPS4 increases both cellular and secreted APP. Values are normalized against actin and expressed as percentage of control, n > 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. e Cellular full length APP is increased in cells transfected with dnVPS4A-FLAG (lower panel) compared to control plasmid Ctr-FLAG (upper panel). Scale bar 25 μm. f Antibody OC labelling of fibrillar oligomers and fibrils is increased in cells transfected with dnVPS4A (arrows) compared to control plasmid. Scale bar 25 μm. g Antibody OC labelling in dnVPS4-transfected cells is associated with enlarged vesicles positive for flotillin-1. Scale bar 15 μm. h Aβ42 accumulation in vesicles positive for ESCRT protein Tsg101 in dnVPS4A-transfected cells. Scale bar 25 μm. i Wt primary neurons at 12 DIV transfected with synapsin-dnVPS4A-FLAG or control synapsin-GFP plasmid for 24 h, immunolabelled for Aβ42 and the post-synaptic protein drebrin shows that Aβ42 labelling is increased with expression of dnVPS4A but not with control plasmid. Scale bar 50 μmCC BY · PubMed Central
Fig. 5 Increased cellular levels of Aβ with dnVPS4A expression is consistent with decreased lysosomal degradation. a Bafilomycin A1 (BafA1) treatment had similar effects on Aβ as dnVPS4a, markedly increasing intracellular levels of Aβ and reducing Aβ secretion. Representative Western blot analysis of cell lysates and cell medium from Swe N2a cells treated with 5 nM BafA1 for 24 h and blotted for 6E10 for Aβ and β-actin. b Densitometric quantification of A. Values are normalized against actin and expressed as percentage of untreated control, n = 3, *** p < 0.001. c When the ability of lysosomes to degrade Aβ is abolished by BafA1, blocking Aβ on route to the lysosomes via dnVPS4 does not lead to further Aβ accumulation. Representative Western blots are shown of lysates (left) and medium (right) from Swe N2a cells treated with 5 nM BafA1 6 h after transfection with mock (no plasmid), control plasmid ctrGFP, wtVPS4A or dnVPS4A. Cells were collected 24 h post-transfection, n = 3. d Western blot analysis of isolated exosomes secreted from Swe N2a cells transfected with mock (no plasmid), ctrGFP, wtVPS4 or dnVPS4 for 48 h. Representative blots demonstrate that exosome secretion is not reduced with dnVPS4. Instead, increased amounts of CD63, an exosomal marker postulated to be involved in ESCRT independent ILV formation, is seen in the exosomal fraction from dnVPS4 transfected cells. Flotillin-1, an exosomal marker associated with cholesterol-enriched lipid rafts is also increased in the exosomal fraction from dnVPS4 transfected cells, while the ESCRT-I protein and exosomal marker Tsg101 is not changed, n = 3
Fig. 5 Increased cellular levels of Aβ with dnVPS4A expression is consistent with decreased lysosomal degradation. a Bafilomycin A1 (BafA1) treatment had similar effects on Aβ as dnVPS4a, markedly increasing intracellular levels of Aβ and reducing Aβ secretion. Representative Western blot analysis of cell lysates and cell medium from Swe N2a cells treated with 5 nM BafA1 for 24 h and blotted for 6E10 for Aβ and β-actin. b Densitometric quantification of A. Values are normalized against actin and expressed as percentage of untreated control, n = 3, *** p < 0.001. c When the ability of lysosomes to degrade Aβ is abolished by BafA1, blocking Aβ on route to the lysosomes via dnVPS4 does not lead to further Aβ accumulation. Representative Western blots are shown of lysates (left) and medium (right) from Swe N2a cells treated with 5 nM BafA1 6 h after transfection with mock (no plasmid), control plasmid ctrGFP, wtVPS4A or dnVPS4A. Cells were collected 24 h post-transfection, n = 3. d Western blot analysis of isolated exosomes secreted from Swe N2a cells transfected with mock (no plasmid), ctrGFP, wtVPS4 or dnVPS4 for 48 h. Representative blots demonstrate that exosome secretion is not reduced with dnVPS4. Instead, increased amounts of CD63, an exosomal marker postulated to be involved in ESCRT independent ILV formation, is seen in the exosomal fraction from dnVPS4 transfected cells. Flotillin-1, an exosomal marker associated with cholesterol-enriched lipid rafts is also increased in the exosomal fraction from dnVPS4 transfected cells, while the ESCRT-I protein and exosomal marker Tsg101 is not changed, n = 3CC BY · PubMed Central
Fig. 6 Blocking ESCRT dependent ILV formation increases tau phosphorylation at serine 369 (S396). a Western blot of transfected N2a Swe cells demonstrates increased tau phosphorylation at S396 with expression of dnVPS4A. b Quantification of A shows a 56% increase in levels tau phosphorylated at S396 with dnVPS4A; values are normalized against actin and expressed as percentage of ctrGFP, (n = 5, *p < 0.05)
Fig. 6 Blocking ESCRT dependent ILV formation increases tau phosphorylation at serine 369 (S396). a Western blot of transfected N2a Swe cells demonstrates increased tau phosphorylation at S396 with expression of dnVPS4A. b Quantification of A shows a 56% increase in levels tau phosphorylated at S396 with dnVPS4A; values are normalized against actin and expressed as percentage of ctrGFP, (n = 5, *p < 0.05)CC BY · PubMed Central
Fig. 7 Induction of autophagy partially rescues dnVPS4A induced intracellular accumulation of Aβ. a Expression of dnVPS4A increases levels of LC3β-II, an indicator of autophagy, by 35% (n = 3, *p < 0.05). Representative blot (above) and quantification (below); values are normalized against actin and expressed as percentage of ctrGFP. b dnVPS4A increases levels of p62, an indicator of autophagy, by 52% (n = 3, **p < 0.01). Representative blot (above) and quantification (below); values are normalized against actin and expressed as percentage of ctrGFP. c Chemically induced autophagy by Rapamycin partially rescues the increase in intracellular Aβ from dnVPS4A. 6 h after transfection Swe N2a cells were treated with 1 μM Rapamycin and harvested 24 h post-transfection. Representative blot (above) and quantification (below) demonstrating 35% reduction in intracellular Aβ by Rapamycin on dnVPS4 transfected cells. Values are normalized against actin and expressed as percentage of dnVPS4 (n = 6, **p < 0.01). d Induced autophagy by torin 1 or by starvation significantly reduces intracellular Aβ to levels in dnVPS4 transfected cells. Values are normalized against actin and expressed as percentage of control transfected cells (n = 3, *p < 0.05, **p < 0.01)
Fig. 7 Induction of autophagy partially rescues dnVPS4A induced intracellular accumulation of Aβ. a Expression of dnVPS4A increases levels of LC3β-II, an indicator of autophagy, by 35% (n = 3, *p < 0.05). Representative blot (above) and quantification (below); values are normalized against actin and expressed as percentage of ctrGFP. b dnVPS4A increases levels of p62, an indicator of autophagy, by 52% (n = 3, **p < 0.01). Representative blot (above) and quantification (below); values are normalized against actin and expressed as percentage of ctrGFP. c Chemically induced autophagy by Rapamycin partially rescues the increase in intracellular Aβ from dnVPS4A. 6 h after transfection Swe N2a cells were treated with 1 μM Rapamycin and harvested 24 h post-transfection. Representative blot (above) and quantification (below) demonstrating 35% reduction in intracellular Aβ by Rapamycin on dnVPS4 transfected cells. Values are normalized against actin and expressed as percentage of dnVPS4 (n = 6, **p < 0.01). d Induced autophagy by torin 1 or by starvation significantly reduces intracellular Aβ to levels in dnVPS4 transfected cells. Values are normalized against actin and expressed as percentage of control transfected cells (n = 3, *p < 0.05, **p < 0.01)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 93

Metadata

Authors
Willén, K., Edgar, J. R., Hasegawa, T., Tanaka, N., Futter, C. E., & Gouras, G. K.
Affiliations
  • Lund University (SE)
  • University of Cambridge (GB)
  • Tohoku University (JP)
  • Miyagi Prefectural Hospital Organization (JP)
  • University College London (GB)
Corresponding author
Gouras, Gunnar K.
Venue
Molecular Neurodegeneration
Published
2017-08-23
Volume
12
Issue
1
Pages
61-61
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2746371185
Cited by
86
References
63
Citations by year
2026: 9 · 2025: 10 · 2024: 9 · 2023: 8 · 2022: 15 · 2021: 10 · 2020: 13 · 2019: 5 · 2018: 7
FWCI
5.06
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
Vetenskapsrådet (2011-4698)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta deposition, multivesicular bodies, VPS4A, dominant negative mutation, ESCRT-III, endosomal sorting, amyloid fibril formation, endocytic pathway, tau phosphorylation, autophagy, amyloid plaques, exosomes, lysosomes
MeSH terms
ATPases Associated with Diverse Cellular Activities, Alzheimer Disease, Animals, Lysosomes, Mice, Transgenic, Neurons, Endosomes, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Endosomal Sorting Complexes Required for Transport, Multivesicular Bodies, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A. https://app.cochat.ai/papers/10.1186/s13024-017-0203-y
The paper
Willén, K., Edgar, J. R., Hasegawa, T., Tanaka, N., Futter, C. E., & Gouras, G. K. (2017). Aβ accumulation causes MVB enlargement and is modelled by dominant negative VPS4A. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-017-0203-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.